Clinical trials recruiting for Pancreatic Cancer Metastatic
16
Recruiting trials
33
US states with sites
15
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| New York | 6 |
| California | 5 |
| Arizona | 4 |
| Florida | 4 |
| Ohio | 4 |
| Texas | 4 |
| Illinois | 3 |
| Maryland | 3 |
| Minnesota | 3 |
| New Jersey | 3 |
| Tennessee | 3 |
| Virginia | 3 |
Top cities
New York, New York 5Chicago, Illinois 3Fairfax, Virginia 3Maumee, Ohio 3Nashville, Tennessee 3Atlanta, Georgia 2Baltimore, Maryland 2Boston, Massachusetts 2Houston, Texas 2Salt Lake City, Utah 2
Self-screener
Recruiting trials
- A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
- A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer
- A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer
- Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Clinical Study of Carbon Ion Radiotherapy for Pancreatic Cancer.
- Conversion Surgery Vs. Palliative Care in Pancreatic Cancer Oligometastatic to the Liver
- EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
- Holistic Acupuncture for Patients With Chemotherapy Induced Nausea
- Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer
- PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)
- Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer
- Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
- Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
- Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Related conditions
Trials recruiting for Pancreatic Cancer Metastatic often also study these conditions. Each links to its own recruiting-trial list.
Pancreatic cancer 870PDAC - Pancreatic Ductal Adenocarcinoma 21PDAC 11Pancreatic Ductal Adenocarcinoma (PDAC) 32Pancreatic Adenocarcinoma Metastatic 6Pancreatic Adenocarcinoma 49Colorectal cancer 1359Prostate cancer 1234Pancreatic Ductal Adenocarcinoma 64Pancreatic Cancer Non-resectable 10
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Pancreatic Cancer Metastatic trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.